Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its holdings in Allergan plc (NYSE:AGN) by 2.1% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 66,585 shares of the company’s stock after acquiring an additional 1,353 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in Allergan were worth $11,792,000 as of its most recent SEC filing.
Several other large investors have also bought and sold shares of AGN. Tredje AP fonden increased its holdings in Allergan by 11.0% in the 1st quarter. Tredje AP fonden now owns 39,611 shares of the company’s stock valued at $6,322,000 after purchasing an additional 3,940 shares in the last quarter. National Asset Management Inc. boosted its position in shares of Allergan by 55.6% in the first quarter. National Asset Management Inc. now owns 9,950 shares of the company’s stock worth $1,763,000 after buying an additional 3,554 shares during the period. Chase Investment Counsel Corp acquired a new stake in shares of Allergan in the first quarter valued at about $1,195,000. AGF Investments Inc. purchased a new stake in shares of Allergan during the 1st quarter valued at about $250,000. Finally, Commerce Bank lifted its position in Allergan by 25.7% during the 1st quarter. Commerce Bank now owns 9,028 shares of the company’s stock worth $1,599,000 after acquiring an additional 1,846 shares in the last quarter. Institutional investors and hedge funds own 83.91% of the company’s stock.
Shares of AGN stock remained flat at $$193.02 during trading hours on Friday. 12,442,653 shares of the stock traded hands, compared to its average volume of 4,008,576. The company has a market cap of $63.50 billion, a PE ratio of -12.07, a price-to-earnings-growth ratio of 1.63 and a beta of 1.20. Allergan plc has a twelve month low of $114.27 and a twelve month high of $202.21. The firm has a 50 day moving average price of $185.22 and a 200-day moving average price of $187.00. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.01 and a quick ratio of 0.84.
The company also recently announced a quarterly dividend, which will be paid on Monday, June 15th. Shareholders of record on Thursday, April 16th will be issued a dividend of $0.74 per share. This represents a $2.96 dividend on an annualized basis and a yield of 1.53%. The ex-dividend date is Wednesday, April 15th. Allergan’s dividend payout ratio is presently 16.78%.
Several brokerages have recently weighed in on AGN. ValuEngine upgraded shares of Allergan from a “sell” rating to a “hold” rating in a research note on Tuesday, March 24th. SunTrust Banks cut shares of Allergan from a “buy” rating to a “hold” rating and upped their price objective for the company from $191.00 to $193.00 in a research report on Tuesday, April 21st. Finally, Cfra lowered Allergan from a “buy” rating to a “hold” rating in a research report on Wednesday, March 25th. Fourteen research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $183.73.
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Featured Story: Trading Strategy
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.